Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 371

1.

Myeloid apolipoprotein E controls dendritic cell antigen presentation and T cell activation.

Bonacina F, Coe D, Wang G, Longhi MP, Baragetti A, Moregola A, Garlaschelli K, Uboldi P, Pellegatta F, Grigore L, Da Dalt L, Annoni A, Gregori S, Xiao Q, Caruso D, Mitro N, Catapano AL, Marelli-Berg FM, Norata GD.

Nat Commun. 2018 Aug 6;9(1):3083. doi: 10.1038/s41467-018-05322-1.

2.

PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor.

Da Dalt L, Ruscica M, Bonacina F, Balzarotti G, Dhyani A, Di Cairano E, Baragetti A, Arnaboldi L, De Metrio S, Pellegatta F, Grigore L, Botta M, Macchi C, Uboldi P, Perego C, Catapano AL, Norata GD.

Eur Heart J. 2018 Jul 2. doi: 10.1093/eurheartj/ehy357. [Epub ahead of print]

PMID:
29982592
3.

High density lipoprotein cholesterol and cancer: Marker or causative?

Pirro M, Ricciuti B, Rader DJ, Catapano AL, Sahebkar A, Banach M.

Prog Lipid Res. 2018 Jul;71:54-69. doi: 10.1016/j.plipres.2018.06.001. Epub 2018 Jun 4. Review.

PMID:
29879431
4.

PCSK9 inhibition and Lp(a) reduction: another piece of the puzzle?

Pirillo A, Catapano AL.

Eur Heart J. 2018 Jul 14;39(27):2586-2588. doi: 10.1093/eurheartj/ehy311. No abstract available.

PMID:
29868825
5.

Biological consequences of dysfunctional HDL.

Pirillo A, Catapano AL, Norata GD.

Curr Med Chem. 2018 May 29. doi: 10.2174/0929867325666180530110543. [Epub ahead of print]

PMID:
29848265
6.

Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract.

Mach F, Ray KK, Wiklund O, Corsini A, Catapano AL, Bruckert E, De Backer G, Hegele RA, Hovingh GK, Jacobson TA, Krauss RM, Laufs U, Leiter LA, März W, Nordestgaard BG, Raal FJ, Roden M, Santos RD, Stein EA, Stroes ES, Thompson PD, Tokgözoglu L, Vladutiu GD, Gencer B, Stock JK, Ginsberg HN, Chapman MJ; European Atherosclerosis Society Consensus Panel.

Eur Heart J. 2018 Jul 14;39(27):2526-2539. doi: 10.1093/eurheartj/ehy182.

7.

Regulatory T Cell Migration Is Dependent on Glucokinase-Mediated Glycolysis.

Kishore M, Cheung KCP, Fu H, Bonacina F, Wang G, Coe D, Ward EJ, Colamatteo A, Jangani M, Baragetti A, Matarese G, Smith DM, Haas R, Mauro C, Wraith DC, Okkenhaug K, Catapano AL, De Rosa V, Norata GD, Marelli-Berg FM.

Immunity. 2018 Apr 17;48(4):831-832. doi: 10.1016/j.immuni.2018.03.034. No abstract available.

8.

Proprotein Convertase Subtilisin Kexin 9 Inhibitors.

Pirillo A, Catapano AL.

Cardiol Clin. 2018 May;36(2):241-256. doi: 10.1016/j.ccl.2017.12.006. Review.

PMID:
29609754
9.

New prospects for PCSK9 inhibition?

Landmesser U, Chapman MJ, Stock JK, Amarenco P, Belch JJF, Borén J, Farnier M, Ference BA, Gielen S, Graham I, Grobbee DE, Hovingh GK, Lüscher TF, Piepoli MF, Ray KK, Stroes ES, Wiklund O, Windecker S, Zamorano JL, Pinto F, Tokgözoglu L, Bax JJ, Catapano AL; European Society of Cardiology/European Atherosclerosis Society Task Force.

Eur Heart J. 2018 Jul 14;39(27):2600-2601. doi: 10.1093/eurheartj/ehy147. No abstract available.

PMID:
29579192
10.

Zc3h10 is a novel mitochondrial regulator.

Audano M, Pedretti S, Cermenati G, Brioschi E, Diaferia GR, Ghisletti S, Cuomo A, Bonaldi T, Salerno F, Mora M, Grigore L, Garlaschelli K, Baragetti A, Bonacina F, Catapano AL, Norata GD, Crestani M, Caruso D, Saez E, De Fabiani E, Mitro N.

EMBO Rep. 2018 Apr;19(4). pii: e45531. doi: 10.15252/embr.201745531. Epub 2018 Mar 5.

PMID:
29507079
11.

Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: Insights from Italian general practice.

Arca M, Ansell D, Averna M, Fanelli F, Gorcyca K, Iorga ŞR, Maggioni AP, Paizis G, Tomic R, Catapano AL.

Atherosclerosis. 2018 Apr;271:120-127. doi: 10.1016/j.atherosclerosis.2018.02.024. Epub 2018 Feb 17.

12.

The Interplay of Lipids, Lipoproteins, and Immunity in Atherosclerosis.

Pirillo A, Bonacina F, Norata GD, Catapano AL.

Curr Atheroscler Rep. 2018 Feb 14;20(3):12. doi: 10.1007/s11883-018-0715-0. Review.

PMID:
29445885
13.

Proprotein Convertase Subtilisin-Kexin type-9 (PCSK9) and triglyceride-rich lipoprotein metabolism: Facts and gaps.

Baragetti A, Grejtakova D, Casula M, Olmastroni E, Jotti GS, Norata GD, Catapano AL, Bellosta S.

Pharmacol Res. 2018 Apr;130:1-11. doi: 10.1016/j.phrs.2018.01.025. Epub 2018 Feb 8. Review.

PMID:
29428206
14.

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias.

Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Monique Verschuren WM, Vlachopoulos C, Wood DA, Luis Zamorano J; Additional Contributor, Cooney MT.

Rev Esp Cardiol (Engl Ed). 2017 Feb;70(2):115. doi: 10.1016/j.rec.2017.01.002. English, Spanish. No abstract available.

PMID:
29389351
15.

The challenge of risk prediction: How good are we?

Tokgozoglu L, Catapano AL.

Eur J Prev Cardiol. 2018 Mar;25(4):418-419. doi: 10.1177/2047487317753893. Epub 2018 Jan 19. No abstract available.

PMID:
29350058
16.

Dyslipidaemias in 2017: Atherogenic lipoproteins as treatment targets.

Catapano AL.

Nat Rev Cardiol. 2018 Jan 16;15(2):75-76. doi: 10.1038/nrcardio.2017.221. No abstract available.

PMID:
29336436
17.

Prevalence and management of familial hypercholesterolemia in patients with coronary artery disease: The heredity survey.

Faggiano P, Pirillo A, Griffo R, Ambrosetti M, Pedretti R, Scorcu G, Werren M, Febo O, Malfatto G, Favretto G, Sarullo F, Antonini-Canterin F, Zobbi G, Temporelli P, Catapano AL; Centro Studi e Formazione - Italian Association for Cardiovascular Prevention and Rehabilitation.

Int J Cardiol. 2018 Feb 1;252:193-198. doi: 10.1016/j.ijcard.2017.10.105.

PMID:
29249427
18.

New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk.

Graham I, Shear C, De Graeff P, Boulton C, Catapano AL, Stough WG, Carlsson SC, De Backer G, Emmerich J, Greenfeder S, Kim AM, Lautsch D, Nguyen T, Nissen SE, Prasad K, Ray KK, Robinson JG, Sasiela WJ, Bruins Slot K, Stroes E, Thuren T, Van der Schueren B, Velkovski-Rouyer M, Wasserman SM, Wiklund O, Zouridakis E; European Society of Cardiology Cardiovascular Roundtable .

Eur Heart J Cardiovasc Pharmacother. 2018 Apr 1;4(2):119-127. doi: 10.1093/ehjcvp/pvx031.

PMID:
29194462
19.

Regulatory T Cell Migration Is Dependent on Glucokinase-Mediated Glycolysis.

Kishore M, Cheung KCP, Fu H, Bonacina F, Wang G, Coe D, Ward EJ, Colamatteo A, Jangani M, Baragetti A, Matarese G, Smith DM, Haas R, Mauro C, Wraith DC, Okkenhaug K, Catapano AL, De Rosa V, Norata GD, Marelli-Berg FM.

Immunity. 2017 Nov 21;47(5):875-889.e10. doi: 10.1016/j.immuni.2017.10.017. Erratum in: Immunity. 2018 Apr 17;48(4):831-832.

20.

Disease trends over time and CD4+CCR5+ T-cells expansion predict carotid atherosclerosis development in patients with systemic lupus erythematosus.

Baragetti A, Ramirez GA, Magnoni M, Garlaschelli K, Grigore L, Berteotti M, Scotti I, Bozzolo E, Berti A, Camici PG, Catapano AL, Manfredi AA, Ammirati E, Norata GD.

Nutr Metab Cardiovasc Dis. 2018 Jan;28(1):53-63. doi: 10.1016/j.numecd.2017.09.001. Epub 2017 Sep 18.

PMID:
29150407
21.

Monocyte and haematopoietic progenitor reprogramming as common mechanism underlying chronic inflammatory and cardiovascular diseases.

Hoogeveen RM, Nahrendorf M, Riksen NP, Netea MG, de Winther MPJ, Lutgens E, Nordestgaard B, Neidhart M, Stroes ESG, Catapano AL, Bekkering S.

Eur Heart J. 2017 Oct 24. doi: 10.1093/eurheartj/ehx581. [Epub ahead of print]

22.

Targeting Cholesterol in Non-ischemic Heart Failure: A Role for LDLR Gene Therapy?

Catapano AL, Pirillo A, Norata GD.

Mol Ther. 2017 Nov 1;25(11):2435-2437. doi: 10.1016/j.ymthe.2017.10.008. Epub 2017 Oct 19. No abstract available.

PMID:
29056399
23.

2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia.

Landmesser U, Chapman MJ, Stock JK, Amarenco P, Belch JJF, Borén J, Farnier M, Ference BA, Gielen S, Graham I, Grobbee DE, Hovingh GK, Lüscher TF, Piepoli MF, Ray KK, Stroes ES, Wiklund O, Windecker S, Zamorano JL, Pinto F, Tokgözoglu L, Bax JJ, Catapano AL.

Eur Heart J. 2018 Apr 7;39(14):1131-1143. doi: 10.1093/eurheartj/ehx549. No abstract available.

PMID:
29045644
24.
25.

miR-30c-5p regulates macrophage-mediated inflammation and pro-atherosclerosis pathways.

Ceolotto G, Giannella A, Albiero M, Kuppusamy M, Radu C, Simioni P, Garlaschelli K, Baragetti A, Catapano AL, Iori E, Fadini GP, Avogaro A, Vigili de Kreutzenberg S.

Cardiovasc Res. 2017 Nov 1;113(13):1627-1638. doi: 10.1093/cvr/cvx157.

PMID:
29016810
26.

Detection of familial hypercholesterolemia in patients from a general practice database.

Casula M, Catapano AL, Rossi Bernardi L, Visconti M, Aronica A.

Atheroscler Suppl. 2017 Oct;29:25-30. doi: 10.1016/j.atherosclerosissup.2017.07.004.

27.

Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study.

Pirillo A, Garlaschelli K, Arca M, Averna M, Bertolini S, Calandra S, Tarugi P, Catapano AL; LIPIGEN Group.

Atheroscler Suppl. 2017 Oct;29:17-24. doi: 10.1016/j.atherosclerosissup.2017.07.002.

28.

Familial hypercholesterolemia: The Italian Atherosclerosis Society Network (LIPIGEN).

Averna M, Cefalù AB, Casula M, Noto D, Arca M, Bertolini S, Calandra S, Catapano AL, Tarugi P; LIPIGEN Group.

Atheroscler Suppl. 2017 Oct;29:11-16. doi: 10.1016/j.atherosclerosissup.2017.07.001.

29.

Good adherence to therapy with statins reduces the risk of adverse clinical outcomes even among very elderly. Evidence from an Italian real-life investigation.

Corrao G, Monzio Compagnoni M, Franchi M, Cantarutti A, Pugni P, Merlino L, Catapano AL, Mancia G.

Eur J Intern Med. 2018 Jan;47:25-31. doi: 10.1016/j.ejim.2017.09.023. Epub 2017 Sep 27.

PMID:
28958460
30.

Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives.

Catapano AL, Pirillo A, Norata GD.

Vasc Health Risk Manag. 2017 Sep 4;13:343-351. doi: 10.2147/VHRM.S130338. eCollection 2017. Review.

31.

Strategies for the use of nonstatin therapies.

Pirillo A, Norata GD, Catapano AL.

Curr Opin Lipidol. 2017 Dec;28(6):458-464. doi: 10.1097/MOL.0000000000000459. Review.

PMID:
28914630
32.

Clinical significance of diabetes likely induced by statins: Evidence from a large population-based cohort.

Corrao G, Monzio Compagnoni M, Rea F, Merlino L, Catapano AL, Mancia G.

Diabetes Res Clin Pract. 2017 Nov;133:60-68. doi: 10.1016/j.diabres.2017.08.008. Epub 2017 Aug 19.

34.

Optimizing Cholesterol Treatment in Patients With Muscle Complaints.

Rosenson RS, Baker S, Banach M, Borow KM, Braun LT, Bruckert E, Brunham LR, Catapano AL, Elam MB, Mancini GBJ, Moriarty PM, Morris PB, Muntner P, Ray KK, Stroes ES, Taylor BA, Taylor VH, Watts GF, Thompson PD.

J Am Coll Cardiol. 2017 Sep 5;70(10):1290-1301. doi: 10.1016/j.jacc.2017.07.752. Review.

PMID:
28859793
35.

Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk.

Ference BA, Kastelein JJP, Ginsberg HN, Chapman MJ, Nicholls SJ, Ray KK, Packard CJ, Laufs U, Brook RD, Oliver-Williams C, Butterworth AS, Danesh J, Smith GD, Catapano AL, Sabatine MS.

JAMA. 2017 Sep 12;318(10):947-956. doi: 10.1001/jama.2017.11467.

36.

PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans.

Baragetti A, Balzarotti G, Grigore L, Pellegatta F, Guerrini U, Pisano G, Fracanzani AL, Fargion S, Norata GD, Catapano AL.

Eur J Prev Cardiol. 2017 Nov;24(17):1870-1877. doi: 10.1177/2047487317724342. Epub 2017 Jul 31.

PMID:
28758421
37.

Efficacy and Safety of Alternate-Day Versus Daily Dosing of Statins: a Systematic Review and Meta-Analysis.

Awad K, Mikhailidis DP, Toth PP, Jones SR, Moriarty P, Lip GYH, Muntner P, Catapano AL, Pencina MJ, Rosenson RS, Rysz J, Banach M; Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group.

Cardiovasc Drugs Ther. 2017 Aug;31(4):419-431. doi: 10.1007/s10557-017-6743-0. Review.

PMID:
28741244
38.

PCSK9 inhibition in statin-intolerant HeFH patients: What's new?

Casula M, Pirillo A, Norata GD, Catapano AL.

Eur J Prev Cardiol. 2017 Sep;24(14):1525-1527. doi: 10.1177/2047487317721980. Epub 2017 Jul 21. No abstract available.

PMID:
28728483
39.

Pitavastatin and HDL: Effects on plasma levels and function(s).

Pirillo A, Catapano AL.

Atheroscler Suppl. 2017 Jul;27:e1-e9. doi: 10.1016/j.atherosclerosissup.2017.05.001. Epub 2017 May 19. Review.

40.

[2016 European guidelines on cardiovascular disease prevention in clinical practice. The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts. Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation].

Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT, Corrà U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FDR, Løchen ML, Löllgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N, Smulders Y, Tiberi M, van der Worp HB, van Dis I, Verschuren WMM.

G Ital Cardiol (Rome). 2017 Jul-Aug;18(7):547-612. doi: 10.1714/2729.27821. Italian. No abstract available.

PMID:
28714997
41.

Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia.

Ferrari R, Aguiar C, Alegria E, Bonadonna RC, Cosentino F, Elisaf M, Farnier M, Ferrières J, Filardi PP, Hancu N, Kayikcioglu M, Mello E Silva A, Millan J, Reiner Ž, Tokgozoglu L, Valensi P, Viigimaa M, Vrablik M, Zambon A, Zamorano JL, Catapano AL.

Eur Heart J Suppl. 2016 Apr 12;18(Suppl C):C2-C12. doi: 10.1093/eurheartj/suw009.

PMID:
28533705
42.

Residual cardiovascular risk.

Ferrari R, Catapano AL.

Eur Heart J Suppl. 2016 Apr 12;18(Suppl C):C1. doi: 10.1093/eurheartj/suw010. No abstract available.

PMID:
28533704
43.

Current guidelines on prevention with a focus on dyslipidemias.

Graham IM, Catapano AL, Wong ND.

Cardiovasc Diagn Ther. 2017 Apr;7(Suppl 1):S4-S10. doi: 10.21037/cdt.2017.04.04. Review.

44.

Identification and Management of Statin-Associated Symptoms in Clinical Practice: Extension of a Clinician Survey to 12 Further Countries.

Rosenson RS, Gandra SR, McKendrick J, Dent R, Wieffer H, Cheng LI, Catapano AL, Oh P, Kees Hovingh G, Stroes ES.

Cardiovasc Drugs Ther. 2017 Apr;31(2):187-195. doi: 10.1007/s10557-017-6727-0.

45.

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.

Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, Hegele RA, Krauss RM, Raal FJ, Schunkert H, Watts GF, Borén J, Fazio S, Horton JD, Masana L, Nicholls SJ, Nordestgaard BG, van de Sluis B, Taskinen MR, Tokgözoglu L, Landmesser U, Laufs U, Wiklund O, Stock JK, Chapman MJ, Catapano AL.

Eur Heart J. 2017 Aug 21;38(32):2459-2472. doi: 10.1093/eurheartj/ehx144. Review.

46.

Practical aspects in the management of statin-associated muscle symptoms (SAMS).

Laufs U, Filipiak KJ, Gouni-Berthold I, Catapano AL; SAMS expert working group.

Atheroscler Suppl. 2017 Apr;26:45-55. doi: 10.1016/S1567-5688(17)30024-7. Review.

PMID:
28434484
47.

Management of Dyslipidemias in Europe and the USA: Same Evidence, Different Conclusions? Can We Find Common Ground?

Graham IM, Catapano AL.

Curr Cardiol Rep. 2017 Jun;19(6):49. doi: 10.1007/s11886-017-0857-7. Review.

PMID:
28432660
48.

Statin use and risk of new-onset diabetes: A meta-analysis of observational studies.

Casula M, Mozzanica F, Scotti L, Tragni E, Pirillo A, Corrao G, Catapano AL.

Nutr Metab Cardiovasc Dis. 2017 May;27(5):396-406. doi: 10.1016/j.numecd.2017.03.001. Epub 2017 Mar 10. Review.

49.

Automatic identification of variables in epidemiological datasets using logic regression.

Lorenz MW, Abdi NA, Scheckenbach F, Pflug A, Bülbül A, Catapano AL, Agewall S, Ezhov M, Bots ML, Kiechl S, Orth A; PROG-IMT study group.

BMC Med Inform Decis Mak. 2017 Apr 13;17(1):40. doi: 10.1186/s12911-017-0429-1.

50.

Efficacy of alirocumab according to background statin type and dose: pooled analysis of 8 ODYSSEY Phase 3 clinical trials.

Catapano AL, Lee LV, Louie MJ, Thompson D, Bergeron J, Krempf M.

Sci Rep. 2017 Apr 4;7:45788. doi: 10.1038/srep45788.

Supplemental Content

Loading ...
Support Center